CRISPR Therapeutics AG
CRSP
$41.86
$3.298.53%
NASDAQ
| 03/31/2025 | 12/31/2024 | ||||
|---|---|---|---|---|---|
| Revenue | -97.58% | 5,828.74% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -97.58% | 5,828.74% | |||
| Cost of Revenue | 58.23% | -11.96% | |||
| Gross Profit | -177.91% | 49.88% | |||
| SG&A Expenses | 6.47% | 4.05% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 48.87% | -9.44% | |||
| Operating Income | -129.80% | 41.35% | |||
| Income Before Tax | -268.43% | 56.96% | |||
| Income Tax Expenses | 58.43% | -20.09% | |||
| Earnings from Continuing Operations | -264.49% | 56.59% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | -264.49% | 56.59% | |||
| EBIT | -129.80% | 41.35% | |||
| EBITDA | -140.50% | 43.31% | |||
| EPS Basic | -262.46% | 56.70% | |||
| Normalized Basic EPS | -266.45% | 57.09% | |||
| EPS Diluted | -262.46% | 56.77% | |||
| Normalized Diluted EPS | -266.45% | 57.09% | |||
| Average Basic Shares Outstanding | 0.56% | 0.27% | |||
| Average Diluted Shares Outstanding | 0.56% | 0.27% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||